MGC Pharmaceuticals Limited
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Roby Reuven Zomer
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1202 Hay Street West Perth WA Australia 6005
- IPO Date
- Feb 22, 2017
- Website
- mgcpharma.com.au
- Similar Companies
- Business
- MGC Pharmaceuticals Limited (Ticker: MGCLF) is a biotechnology company specializing in the research, development, and commercialization of cannabinoid-based pharmaceutical products and health supplements. The company offers a diverse range of products including medicinal cannabis formulations, botanical extracts, oils, and topical applications targeted for therapeutic use in various medical conditions. Its core product lines include standardized cannabinoid medicines, proprietary pharmaceutical-grade cannabis products, and related health and wellness solutions. MGC Pharmaceuticals operates primarily in the medical cannabis industry and serves markets across Europe, Australia, and other international regions. Founded in 2015, the company is headquartered in Adelaide, South Australia. In the last 1-2 years, MGC Pharmaceuticals has undertaken significant strategic initiatives including expanding its product portfolio with new medicinal cannabis formulations and launching partnerships aimed at enhancing research capabilities and market access. The company has increased R&D efforts to develop next-generation cannabinoid-based therapies and has expanded its operational footprint in Europe through new licensing agreements and distribution deals. Additionally, MGC Pharmaceuticals has focused on scaling production technology to support commercial growth and has integrated new clinical service offerings aligned with emerging therapeutic trends in cannabinoid medicine. MGC Pharmaceuticals operates through its subsidiaries and maintains a presence in key regulatory markets, targeting healthcare providers, pharmaceutical distributors, and patients requiring cannabinoid-based treatments. The company’s offerings encompass pharmaceutical-grade products tailored for conditions such as epilepsy, chronic pain, and other therapeutic areas requiring cannabinoid intervention. MGC continues to emphasize scientific validation and regulatory compliance as foundational pillars of its business strategy.
Argent BioPharma hails US listing; appoints new CFO
MGC Pharma reports progress 'across all fronts'
MGC Pharma Rebrands as Argent BioPharma in Strategic Transformation
MGC Pharmaceuticals unveils fundraise as global push planned
MGC Pharmaceuticals granted Saudi FDA approval for ArtemiC™
MGC Pharma receives Saudi approval for ArtemiC
MGC Pharmaceuticals clarifies share consolidation and new fundraise
MGC Pharmaceuticals proposes financial and capital restructuring plan
MGC Pharmaceuticals hails pivot to medical products, legacy sales hit
MGC Pharmaceuticals proposes fundraising for Australian investors
MGC Pharma hails good quarter as UK patients get CannEpil
Small-cap movers: MGC Pharma, Versarien and the end of cheap money
MGC Pharmaceuticals raises £0.7mln for working capital
MGC Pharmaceuticals clarifies shape of recent AMC Pharma order
MGC Pharma bags $1 million US order
MGC Pharma dismisses executive for share trading breaches
Wall Street set for higher open as debt deal is sealed ahead of May jobs report
CBI to axe staff as it fights for survival
MGC Pharmaceuticals delivers first CannEpil doses to UK patients; opens doors for refractory epilepsy treatment
MGC Pharmaceuticals announces boardroom changes, reflecting its shift of focus